The binding sites for benztropines and dopamine in the dopamine transporter overlap.
Analogs of benztropines (BZTs) are potent inhibitors of the dopamine transporter (DAT) but are less effective than cocaine as behavioral stimulants. As a result, there have been efforts to evaluate these compounds as leads for potential medication for cocaine addiction. Here we use computational modeling together with site-directed mutagenesis to characterize the binding site for BZTs in DAT. Docking into molecular models based on the structure of the bacterial homolog LeuT supported a BZT binding site that overlaps with the substrate-binding pocket. In agreement, mutations of residues within the pocket, including(2) Val152(3.46) to Ala or Ile, Ser422(8.60) to Ala and Asn157(3.51) to Cys or Ala, resulted in decreased affinity for BZT and the analog JHW007, as assessed in [(3)H]dopamine uptake inhibition assays and/or [(3)H]CFT competition binding assay. A putative polar interaction of one of the phenyl ring fluorine substituents in JHW007 with Asn157(3.51) was used as a criterion for determining likely binding poses and establish a structural context for the mutagenesis findings. The analysis positioned the other fluorine-substituted phenyl ring of JHW007 in close proximity to Ala479(10.51)/Ala480(10.52) in transmembrane segment (TM) 10. The lack of such an interaction for BZT led to a more tilted orientation, as compared to JHW007, bringing one of the phenyl rings even closer to Ala479(10.51)/Ala480(10.52). Mutation of Ala479(10.51) and Ala480(10.52) to valines supported these predictions with a larger decrease in the affinity for BZT than for JHW007. Summarized, our data suggest that BZTs display a classical competitive binding mode with binding sites overlapping those of cocaine and dopamine.
Bisgaard
Heidi
H
Molecular Neuropharmacology Laboratory, Department of Neuroscience and Pharmacology, Faculty of Health Sciences, The Panum Institute, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Larsen
M Andreas B
MA
Mazier
Sonia
S
Beuming
Thijs
T
Newman
Amy Hauck
AH
Weinstein
Harel
H
Shi
Lei
L
Loland
Claus J
CJ
Gether
Ulrik
U
D000818:Animals; D001590:Benztropine / Q000378:metabolism / Q000494:pharmacology*; D001665:Binding Sites; D019556:COS Cells; D002522:Chlorocebus aethiops; D003042:Cocaine / Q000378:metabolism / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism*; D008958:Models, Molecular; D013329:Structure-Activity Relationship
D050483:Dopamine Plasma Membrane Transport Proteins; D001590:Benztropine; D003042:Cocaine; D004298:Dopamine
J Pharmacol Exp Ther. 2004 May;309(2):650-60
14755006
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1683-8
11818545
Eur J Pharmacol. 2003 Oct 31;479(1-3):71-82
14612139
Nat Chem Biol. 2010 Feb;6(2):109-16
20081826
Nature. 2007 Aug 23;448(7156):952-6
17687333
Eur J Pharmacol. 2003 May 9;468(2):109-19
12742518
Science. 2008 Dec 12;322(5908):1655-61
19074341
Nature. 2005 Sep 8;437(7056):215-23
16041361
Mol Pharmacol. 2002 Apr;61(4):885-91
11901228
Nat Neurosci. 2008 Jul;11(7):780-9
18568020
Nat Struct Mol Biol. 2009 Jun;16(6):652-7
19430461
J Pharmacol Exp Ther. 2003 Nov;307(2):801-8
12966155
J Med Chem. 2006 Jan 26;49(2):534-53
16420040
J Biol Chem. 2008 Jun 20;283(25):17691-701
18426798
Eur J Pharmacol. 2003 Oct 31;479(1-3):93-106
14612141
Nature. 2009 May 21;459(7245):347-55
19458710
Pharm Res. 2005 Apr;22(4):603-12
15846468
Pflugers Arch. 2004 Feb;447(5):519-31
12719981
J Neurosci. 2005 Feb 23;25(8):1889-93
15728828
J Phys Chem B. 2009 Nov 12;113(45):15057-66
19831380
Trends Pharmacol Sci. 2006 Jul;27(7):375-83
16762425
J Biol Chem. 2006 Jan 27;281(4):2012-23
16272152
J Biol Chem. 1999 Dec 24;274(52):36928-34
10601246
J Biol Chem. 2010 Mar 12;285(11):8363-74
19948720
Science. 2007 Sep 7;317(5843):1390-3
17690258
Synapse. 2005 Nov;58(2):72-94
16088952
Eur J Pharmacol. 2003 Oct 31;479(1-3):3-12
14612133
Mol Pharmacol. 2006 Nov;70(5):1630-42
16880288
J Biol Chem. 1997 Nov 7;272(45):28321-7
9353288
Med Res Rev. 2002 Sep;22(5):429-64
12210554
J Am Chem Soc. 2010 Feb 3;132(4):1311-22
20055463
Mol Pharmacol. 2008 Mar;73(3):813-23
17978168
Curr Opin Neurobiol. 2007 Jun;17(3):304-12
17509873
J Med Chem. 1997 Dec 19;40(26):4329-39
9435902
J Biol Chem. 2004 Jan 30;279(5):3228-38
14597628
Annu Rev Pharmacol Toxicol. 2003;43:261-84
12359863
J Med Chem. 2004 Jan 15;47(2):337-44
14711306
J Pharmacol Exp Ther. 2009 May;329(2):677-86
19228996
Br J Pharmacol. 2006 Jan;147 Suppl 1:S82-8
16402124
J Pharm Sci. 2008 May;97(5):1993-2007
17879975
J Biol Chem. 2009 Apr 10;284(15):10276-84
19213730
J Med Chem. 1994 Jul 22;37(15):2258-61
8057273
Mol Pharmacol. 2009 Mar;75(3):514-24
19098122
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9333-8
16754872
Nature. 2007 Oct 11;449(7163):726-30
17704762
Mol Cell. 2008 Jun 20;30(6):667-77
18570870
J Biol Chem. 2010 Jan 15;285(3):2051-63
19892699